116 related articles for article (PubMed ID: 33864110)
1. Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation.
Alshalalfa M; Abou-Ouf H; Davicioni E; Karnes RJ; Alhajj R; Bismar TA
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2223-2231. PubMed ID: 33864110
[TBL] [Abstract][Full Text] [Related]
2. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
Bhanvadia RR; VanOpstall C; Brechka H; Barashi NS; Gillard M; McAuley EM; Vasquez JM; Paner G; Chan WC; Andrade J; De Marzo AM; Han M; Szmulewitz RZ; Vander Griend DJ
Clin Cancer Res; 2018 Aug; 24(15):3668-3680. PubMed ID: 29716922
[No Abstract] [Full Text] [Related]
3. HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
Johng D; Torga G; Ewing CM; Jin K; Norris JD; McDonnell DP; Isaacs WB
Prostate; 2019 Mar; 79(4):414-424. PubMed ID: 30560549
[TBL] [Abstract][Full Text] [Related]
4. MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans.
VanOpstall C; Perike S; Brechka H; Gillard M; Lamperis S; Zhu B; Brown R; Bhanvadia R; Vander Griend DJ
Elife; 2020 Jun; 9():. PubMed ID: 32553107
[TBL] [Abstract][Full Text] [Related]
5. Single-Cell Transcriptome Analysis of Small Cell Neuroendocrine Carcinoma of the Endometrium Reveals
Zhong C; Guo YE; Yang Q; Song Y; Wang T; Cai B; Chen H; Du H; Wan J; Liu Y; Li Y; Wan X
Front Biosci (Landmark Ed); 2024 Mar; 29(3):100. PubMed ID: 38538277
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
7. ONECUT2 is a driver of neuroendocrine prostate cancer.
Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.
Chen JL; Li J; Kiriluk KJ; Rosen AM; Paner GP; Antic T; Lussier YA; Vander Griend DJ
Clin Cancer Res; 2012 Aug; 18(16):4291-302. PubMed ID: 22723371
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
11. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.
Rotinen M; You S; Yang J; Coetzee SG; Reis-Sobreiro M; Huang WC; Huang F; Pan X; Yáñez A; Hazelett DJ; Chu CY; Steadman K; Morrissey CM; Nelson PS; Corey E; Chung LWK; Freedland SJ; Di Vizio D; Garraway IP; Murali R; Knudsen BS; Freeman MR
Nat Med; 2018 Dec; 24(12):1887-1898. PubMed ID: 30478421
[TBL] [Abstract][Full Text] [Related]
12. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM
Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980
[TBL] [Abstract][Full Text] [Related]
13. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
14. ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7.
Guo T; Wen XZ; Li ZY; Han HB; Zhang CG; Bai YH; Xing XF; Cheng XJ; Du H; Hu Y; Wang XH; Jia YN; Nie ML; Xie M; Li QD; Ji JF
Cell Death Dis; 2019 Jan; 10(2):33. PubMed ID: 30674889
[TBL] [Abstract][Full Text] [Related]
15. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin.
Agaimy A; Erlenbach-Wünsch K; Konukiewitz B; Schmitt AM; Rieker RJ; Vieth M; Kiesewetter F; Hartmann A; Zamboni G; Perren A; Klöppel G
Mod Pathol; 2013 Jul; 26(7):995-1003. PubMed ID: 23503646
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
17. Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.
Juhlin CC; Zedenius J; Höög A
Endocr Pathol; 2020 Dec; 31(4):401-410. PubMed ID: 32813226
[TBL] [Abstract][Full Text] [Related]
18. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
[TBL] [Abstract][Full Text] [Related]
19. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors.
Zhao LH; Chen C; Mao CY; Xiao H; Fu P; Xiao HL; Wang G
Pathol Res Pract; 2019 Jul; 215(7):152448. PubMed ID: 31133441
[TBL] [Abstract][Full Text] [Related]
20. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
